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A cute rejection remains a limiting factor in the suc-cess of cardiac allotransplantation. Host sensitized
lymphocytes play a major role, damaging donor heart
myocytes by infiltrating the graft and causing cell
death.1 Two different mechanisms of immunologic
injury have been suggested: necrosis (unregulated cell
death) and apoptosis (programmed cell death). By
inducing apoptosis, T cells can cause lysis of target
cells.2 Recent studies have indicated apoptosis as an
important mechanism of cell death during rejection of
renal,3 hepatic,4 and small-intestinal allografts.5 The
role of apoptosis in rejection of cardiac allografts is
unclear.6-9 Apoptosis has been shown to occur during
cardiac allograft rejection,7,8 and the presence of apop-
totic myocytes in endomyocardial biopsy specimens
correlates with the histologic grade of rejection.7
One of the earliest cellular features of apoptotic cell
death is loss of the normal asymmetry of the cytoplasm
cell membrane.10 Phosphatidylserine is a phospholipid
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that is normally restricted to the inner leaflet of the lipid
bilayer.11 When a cell is committed to programmed cell
death, phosphatidylserine is expressed on the surface.12
The externalization of phosphatidylserine occurs before
the terminal apoptotic changes of membrane bleb for-
mation, condensation of the cytoplasmic matrix and
organelles, condensation of chromatin, and cleavage of
chromatin by endonucleases.13 Currently, apoptosis can
be demonstrated in histologic sections with in situ stain-
ing of these DNA breaks by terminal deoxynucleotidyl-
transferase-mediated deoxyuridine triphosphate–biotin
nick-end labeling imaging (TUNEL).14
Fluorescein-labeled annexin V has been employed to
detect apoptotic cells in vitro by flow cytometry.15
Annexin V is a human protein of 319 amino acids with
a molecular weight of 36 kd and affinity for membrane-
bound phosphatidylserine, both in vitro and in vivo
(dissociation constant 7 nmol/L).15 Recently a novel
technique has been developed to label annexin V with
technetium Tc 99m.16 Hydrazinonicotinamide (HYNIC),
a bifunctional molecule that binds to proteins and con-
jugates 99mTc, was used to create a derivative of annex-
in V before radiolabeling with 99mTc.17
The purpose of this study was to test the hypothesis
that apoptosis is an important mechanism for cardiac
allograft rejection and that technetium Tc 99m annexin
V can be used to detect apoptosis during rejection in
vivo by nuclear imaging. Furthermore, it was hypothe-
sized that 99mTc–annexin V imaging could be used to
monitor immunologically mediated myocyte damage
and cardiac allograft rejection. Histologic signs of re-
jection were correlated with the uptake of 99mTc–
annexin V by the transplanted heart. Finally, the suc-
cessful treatment of rejection with cyclosporine (INN:
ciclosporin) and corticosteroids was correlated with the
uptake of 99mTc–annexin V.
Methods
Animals. Young adult, pathogen free, male ACI (RT1a)
and PVG (RT1c) rats weighing between 200 and 250 g were
used in this study (Harlan Sprague Dawley, Indianapolis,
Ind). Animals were maintained at the animal care facilities of
the Department of Cardiothoracic Surgery, Stanford
University Medical Center, Stanford, Calif, under standard
temperature, humidity, and time-regulated light conditions.
Water and food were provided ad libitum. Animals were
treated in a humane manner, conforming to the “Principles of
Laboratory Animal Care” formulated by the National Society
for Medical Research and the “Guide for the Care and Use of
Laboratory Animals” prepared by the National Academy of
Sciences and published by the National Institutes of Health
(NIH publication No. 86-23, revised 1985). ACI rats served
as recipients of cardiac grafts from allogeneic PVG donor rats
or syngeneic ACI donor rats.
Anesthesia. Before transplantation or nuclear imaging,
animals were anesthetized by inhalation of methoxyflurane
(1%-2%) followed by an intraperitoneal injection of pento-
barbital (40 mg/kg). Heart rate, ventilation rate, and temper-
ature were closely monitored during anesthesia. Rats were
briefly anesthetized with methoxyflurane to facilitate the
administration of medication or the assessment of the graft.
Heart transplantation. Donor cardiac grafts were trans-
planted heterotopically into the abdomens of recipient rats
according to a modification of the technique described by
Ono and Lindsey.18 Native hearts were harvested from donor
animals after treatment with heparin. Donor hearts were per-
fused with Stanford cardioplegia solution and stored in cold
saline solution (0°-4°C). End-to-side anastomoses were made
from the ascending aorta of the donor heart to the abdominal
aorta of the recipient and from the donor pulmonary artery to
the recipient vena cava after ligation of the venae cavae and
pulmonary veins of the donor heart. Ischemic times ranged
between 20 and 30 minutes. Cardiac allograft function was
assessed by daily palpation in 1 control group (n = 6).
Rejection was deemed complete when palpable ventricular
contractions ceased.
Radiolabeling of annexin V. Human annexin V was pro-
duced by expression in Escherichia coli and purified as previ-
ously described elsewhere.19 Annexin V was treated with
HYNIC to form a derivative and then bound to 99mTc accord-
ing to the methods described by Blankenberg and colleagues.20
The specific activity of the 99mTc-HYNIC–annexin V was
between 100 and 200 m Ci/m g protein. Radiologic purity was
>97%, as determined by instant thin-layer chromatography.
Nuclear imaging. Untreated recipient animals with allo-
geneic cardiac grafts (group I, n = 43) and recipient animals
with syngeneic cardiac grafts (group II, n = 23) underwent
nuclear imaging with 99mTc–annexin V daily for 7 days after
transplantation. Animals within groups I and II were killed
immediately after nuclear imaging and on various days after
transplantation, and grafts were procured for histologic and
TUNEL analysis. Animals were injected through the tail vein
with 1.0 mCi 99mTc-HYNIC–annexin V 1 hour before imag-
ing. Recipient rats were anesthetized and placed in the prone
position on a table, and planar imaging was performed in the
anterior projection with a mobile Ohio scintillation camera
(Technicare, Solon, Ohio) with a high-resolution parallel-
hole collimator. A 20% window was centered on the 140 keV
photopeak of 99mTc, and the nuclear image was recorded into
a 256 · 256 matrix of a computer for digital display and
analysis of the image (ICON; Siemens, Hoffman Estates, Ill).
All images were recorded for 10 minutes. Region of interest
analysis was performed to calculate the uptake of
99mTc–annexin V in the transplanted heart. Uptake was
expressed in counts in the region of interest as a percentage
of total body counts.
Immunosuppression. One cohort of animals was treated
with cyclosporine, commencing 4 days after transplantation
(group III, n = 6). Cyclosporine (Sandoz, Basel, Switzerland)
was dissolved in olive oil and administered orally by gavage
at a dose of 10 mg/kg/d. One cohort was treated with
cyclosporine and methylprednisolone commencing 4 days
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after transplantation (group IV, n = 6). Methylprednisolone
was dissolved in saline solution and administered intraperi-
toneally at a dose of 50 mg/kg on day 4, 25 mg/kg/d on days
5 and 6, and 10 mg/kg/d for the rest of the study period.
Groups III and IV underwent nuclear imaging on days 4, 11,
and 18 after transplantation and were killed after imaging on
day 18.
Histopathologic studies. Animals were killed after
nuclear imaging. Samples of the procured transplanted hearts
were fixed in a 10% buffered formalin solution and subse-
quently embedded in paraffin. Paraffin sections of 5 m m were
stained with hematoxylin and eosin to assess histopathologic
changes. Sections were evaluated by 2 separate investigators
in a blinded fashion. Acute rejection was scored in a semi-
quantitive manner (0, no rejection; 1, mild rejection, sparse,
focal or diffuse mononuclear cell infiltrate with no myocyte
damage; 2, moderate rejection, focal or multifocal mononu-
clear cell infiltrate and myocyte damage; or 3, severe rejec-
tion, diffuse mononuclear cell infiltrate and conspicuous
myocyte damage; Fig 1).
TUNEL staining. Nuclear DNA fragmentation was ana-
lyzed by C-terminal TUNEL to assess for apoptosis in 5 m m
paraffin sections with a commercially available peroxidase
kit (Apoptag; Oncor, Gaithersburg, Md). Sections were eval-
uated by 2 separate investigators in a blinded fashion.
Presence of TUNEL-reactive nuclei was assessed for in infil-
trating cells, endothelial cells, and myocytes of cardiac grafts.
At least 20 fields were analyzed at · 400 magnification (0,
none; +, scattered; or ++, many or multifocal distribution).
Small bowels and testes of untreated PVG rats were used as
positive control preparations. Native hearts of untreated PVG
rats were used as negative control preparations.
Statistical analysis. Values are given as mean ± standard
deviation. Differences between groups were analyzed with a
2-tailed Student t test with unequal variance. A 2-tailed paired
Student t test was used to analyze sequential results as appro-
priate. Correlation between values was calculated as the
squared Pearson product moment correlation coefficient (r2).
Results
Histopathologic examination. Rejection of PVG
allografts by untreated ACI recipients (control group)
was complete after 7.5 ± 0.5 days, as indicated by
absence of palpable ventricular contractions. Such his-
tologic signs of rejection as infiltration of mononuclear
cells, however, were clearly present at day 4 in PVG
allografts (group I). The mean histologic grades of
acute rejection on each day after transplantation are
listed in Table I. There was an increase in the grade of
acute rejection each day after transplantation (r2 =
0.91; Fig 2). No signs of rejection were detected in syn-
geneic ACI grafts (group II).
TUNEL studies. TUNEL images of cardiac allo-
grafts with histologic signs of acute rejection all
Fig 1. Histologic grading of acute rejection in rats. Top left: Grade 0, no rejection (hematoxylin and eosin stain;
original magnification · 400). Top right: Grade 1, mild rejection—sparse, focal or diffuse mononuclear cell infil-
trate with no myocyte damage (hematoxylin and eosin stain; original magnification · 400). Bottom left: Grade 2,
moderate rejection—focal or multifocal mononuclear cell infiltrate and myocyte damage (hematoxylin and eosin
stain; original magnification · 400). Bottom right: Grade 3, severe rejection—diffuse mononuclear cell infiltrate
and conspicuous myocyte damage (hematoxylin and eosin stain; original magnification · 200).
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showed scattered apoptotic nuclei in graft-infiltrating
inflammatory cells, endothelial cells, and myocytes.
Apoptotic cells were absent in cardiac grafts that did
not show histologic signs of acute rejection. Specimens
with grade 2 rejection showed many apoptotic nuclei in
inflammatory cells, whereas specimens with grade 3
rejection showed apoptotic nuclei predominantly in the
myocytes (Table II, Fig 3).
Nuclear imaging. Uptake of 99mTc–annexin V was
readily visible on nuclear image of the heterotopically
placed PVG allografts in untreated animals (group I) on
days 4, 5, 6, and 7 after transplantation. Syngeneic ACI
grafts (group II) did not show any detectable uptake of
99mTc–annexin V (Fig 4). Uptake of the radiopharma-
ceutical by syngeneic grafts did not differ from uptake
by the native heart, as confirmed by scintillation well
counting (data not shown).
Uptake of 99mTc–annexin V by transplanted allografts
(group I), measured as a percentage of whole-body
uptake, was not different from that in syngeneic control
animals (group II) on days 1 (allogeneic [n = 5] vs syn-
geneic [n = 3], 42% ± 14% vs 41% ± 10%; P = .72), 2
(allogeneic [n = 6] vs syngeneic [n = 3], 43% ± 17% vs
42% ± 13%; P = .95), and 3 (allogeneic [n = 5] vs syn-
geneic [n = 5], 39% ± 6% vs 35% ± 12%; P = .50).
However, uptake of 99mTc–annexin V by transplanted
allografts (group I) was significantly greater than in
syngeneic control animals (group II) on days 4 (allo-
geneic [n = 4] vs syngeneic [n = 3], 125% ± 44% vs
58% ± 34%; P = .05), 5 (allogeneic [n = 5] vs syn-
geneic [n = 3], 140% ± 53% vs 40% ± 18%; P < .001),
6 (allogeneic [n = 11] vs syngeneic [n = 3], 234% ±
46% vs 46% ± 5%; P < .001), and 7 (allogeneic [n = 6]
vs syngeneic [n = 3], 196% ± 15% vs 40% ± 16%; P =
.013; Fig 5). No toxic effects of intravenous injection
of 99mTc–annexin V were noted.
Correlation between histopathologic examination
and nuclear imaging. After histopathologic examina-
tion and nuclear imaging, the data were further ana-
lyzed according to histologic grade of acute rejection.
Transplanted grafts that showed the same histologic
grade of rejection had similar percentages of uptake of
99mTc–annexin V. The differences in uptake of
99mTc–annexin V between groups were statistically sig-
Fig 2. Correlation between time after transplantation and histologic grade of acute rejection of heterotopic PVG
allografts in untreated ACI rats. Histologic grades are as shown in Fig 1. Rejection was complete after 7.5 ± 0.5
days, as indicated by absence of palpable ventricular contractions.
Table I. Histologic grade of rejection of allogeneic
PVG grafts and syngeneic ACI grafts after transplan-
tation to untreated ACI recipient rats
Allogeneic (N = 43) Syngeneic (N = 23)Days after 
transplantation Grade n Grade n
Day 1 0.0 ± 0.0 5 0.0 ± 0.0 3
Day 2 0.0 ± 0.0 6 0.0 ± 0.0 3
Day 3 0.6 ± 0.2 5 0.0 ± 0.0 5
Day 4 1.3 ± 0.5 4 0.0 ± 0.0 3
Day 5 1.9 ± 0.4 7 0.0 ± 0.0 3
Day 6 2.3 ± 0.5 11 0.0 ± 0.0 3
Day 7 3.0 ± 0.0 6 0.0 ± 0.0 3
Histologic grades, given as mean ± standard deviation, are as shown in Fig 1.
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nificant (Table III). A linear correlation between the
histologic grade of acute rejection and the percentage
of uptake of 99mTc–annexin V was observed (r2 = 0.87;
Fig 6).
Correlation between treatment of rejection and
nuclear imaging. Treatment of ACI recipients of PVG
allografts starting on day 4 after transplantation with
cyclosporine alone (group III) or cyclosporine and
methylprednisolone (group IV) successfully reversed
rejection. All allografts recovered from rejection, as indi-
cated by maintenance of a strong, palpable heartbeat
until day 18, when animals were killed. Histopathologic
analysis confirmed resolution of rejection in both
groups. Occasional sections demonstrated sparse
mononuclear cell infiltration; however, no evidence of
Fig 3. TUNEL staining in representative cardiac grafts. Top left: Absence of apoptosis in a graft that did
not show histologic signs of acute rejection (original magnification, · 400). Top right: Absence of apop-
tosis in a graft after recovery from rejection, after 14 days of treatment with cyclosporine (original mag-
nification · 400). Bottom left: Apoptotic nuclei of inflammatory cells in a graft with grade 2 rejection
(original magnification · 400). Bottom right: Apoptotic nuclei of myocytes in a graft with grade 3 rejec-
tion (original magnification · 400).
Table II. TUNEL: Presence of apoptotic nuclei in
specimens of cardiac grafts with the same histologic
grade of acute rejection (groups I and II), and of cardiac
grafts that had recovered from rejection after treat-
ment with immunosuppressive therapy (group III and
IV)
Inflammatory Endothelial 
Rejection* cells† cells† Myocytes†
Grade 0 (n = 31) 0 0 0
Grade 1 (n = 5) + + +
Grade 2 (n = 10) ++ + +
Grade 3 (n = 14) + + ++
Recovery (n = 12) 0/+ 0 0
Data are from 20 fields, 400 · magnification.
*Grafts that showed grade 0.5 rejection are not included in this table (n = 6).
Fig 4. Uptake of 99mTc–annexin V on day 4 after transplanta-
tion in untreated ACI recipients in an allogeneic graft (arrow,
A, group I) and a syngeneic graft (B, group II). Panels show
representative images on day 4 after transplantation.
FPO
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myocyte damage was observed. TUNEL images of allo-
grafts that had been treated with cyclosporine with or
without methylprednisolone and had recovered from
rejection showed no signs of apoptosis in myocytes or
endothelial cells and only showed extremely occasional
apoptotic nuclei in inflammatory cells after 14 days of
treatment (Table II, Fig 3).
Uptake of 99mTc–annexin V by transplanted allografts
in group III on day 4 after transplantation significantly
increased from that on day 1 (day 4 vs day 1, 1.53 ±
0.68 vs 42% ± 14%, P = .001). Uptake of 99mTc–annex-
in V decreased significantly on day 11 after transplan-
tation, after 7 days of treatment with cyclosporine (day
11 vs day 4, 76% ± 37% vs 153% ± 68%, P = .042).
Uptake of 99mTc–annexin V decreased even further on
day 18 after transplantation, after 14 days of treatment,
to a value comparable with that seen on day 1 after
transplantation (day 18 vs day 4, 34% ± 13% vs 153%
± 68%, P = .007; day 18 vs day 1, 34% ± 13% vs 42%
± 14%; P = .368; Figs 7 and 8).
Uptake of 99mTc–annexin V by transplanted allografts
in group IV decreased in a similar fashion after treat-
ment with cyclosporine and methylprednisolone. It
reached baseline level on day 18 after transplantation,
a pattern essentially the same as that seen in group III
(data not shown).
Discussion
This study was designed to show the feasibility of
using 99mTc–annexin V imaging to detect apoptosis dur-
ing cardiac allograft rejection. The measurement of
intensity of uptake of 99mTc–annexin V leaves room for
improvement. Uptake by the graft, indicated as percent-
age of total body uptake, does not seem to acceptably
indicate the dramatic, visible changes seen in imaging
of rejecting grafts. The kidneys of experimental and
control animals all had marked uptake of 99mTc–annex-
in V. The renal uptake, however, did not preclude imag-
ing of the cardiac grafts. The specific mechanism of
renal binding is uncertain but may relate to the intrinsic
lipid profile of the kidney, with high concentrations of
phosphatidylserine in the cortex.21 Sensitivity and
specificity of 99mTc–annexin V imaging are yet to be
determined. A sharp definition of a positive scan result
is required to calculate the fractions of false-positive
and false-negative results in a larger, prospective study.
Further refinement of the techniques used and well-
designed primate studies will be needed before use of
99mTc–annexin V imaging in human patients.
Table III. Uptake of 99mTc–annexin V, measured as
percentage of total body uptake, compared between
grafts with the same histologic grade of rejection
Rejection* Uptake (%) P†
Grade 0 (n = 31) 0.42 ± 0.17
Grade 1 (n = 5) 0.83 ± 0.31 .036 grade 0
Grade 2 (n = 10) 1.43 ± 0.40 .008 grade 1
Grade 3 (n = 14) 2.40 ± 0.53 <.001 grade 2
Uptake percentages are expressed as mean ± standard deviation.
*Grafts that showed grade 0.5 rejection are not included in this table (n = 6).
†Analyzed with 2-tailed, unpaired Student t test, unequal variance.
Fig 5. Uptake of 99mTc–annexin V, measured as a percentage of total body uptake, in rejecting allogeneic PVG
grafts (group I, filled bars), and nonrejecting syngeneic ACI grafts (group II, open bars), on days 1 through 7
after transplantation in untreated ACI recipients. Uptakes in grafts from groups I and II were compared on each
day by a 2-tailed unpaired Student t test with unequal variance.
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Clinical signs of rejection in cardiac allograft recipi-
ents can be subtle.22 This subtlety necessitates multiple
surveillance endomyocardial biopsies. Endomyocar-
dial biopsy is an invasive procedure that is uncomfort-
able for patients, costly, and associated with morbidity,
such as tricuspid regurgitation.23 False-negative biopsy
results could occur as a result of focal rejection,
because endomyocardial biopsy assesses only random
samples from the right ventricular septum.24 99mTc–
annexin V imaging allows noninvasive examination of
the entire heart and can detect myocyte membrane
changes in an early phase of cellular damage. This per-
Fig 6. Correlation between histologic grade of acute rejection and uptake of 99mTc–annexin V, measured as per-
centage of total body uptake. Histologic grades are as shown in Fig 1. Each data point represents an individual
cardiac graft.
Fig 7. Uptake of 99mTc–annexin V in an allogeneic graft from group III. ACI recipients received cyclosporine
treatment (10 mg/kg/d) starting on day 4 after transplantation. A, Day 1 after transplantation, no treatment. B,
Day 4 after transplantation, start of cyclosporine treatment. C, Day 11 after transplantation, after 7 days of
cyclosporine treatment. D, Day 18 after transplantation, after 14 days of cyclosporine treatment, recovery from
rejection. Panels show representative sequential images from 1 animal.
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mits early treatment, possibly even while cellular
changes are still reversible.
Mechanisms of myocyte damage during cardiac allo-
graft rejection range from apoptosis to necrosis.7,8
Apoptosis is a short-lived focal process of self-inflicted
cell death.25 Loss of the normal asymmetry of the phos-
pholipid bilayer during apoptosis has been shown to
coincide with chromatin condensation before DNA
cleavage by endonucleases.12 99mTc–annexin V detects
apoptosis in an earlier stage than does TUNEL, which
is specific for the later nuclear cleaving of chromatin.13
TUNEL, which requires processed myocardial tissue,
was not abundant in histologic sections, even in reject-
ing allografts that showed a high uptake of 99mTc–
annexin V. The cell membrane remains impermeable
during apoptosis and does not elicit an inflammatory
response by exposure of endocellular substances and
release of harmful enzymes to the surrounding tis-
sues.25 When necrosis occurs, however, the cellular
membrane becomes permeable.25 99mTc–annexin V can
also detect cells undergoing necrosis and bind to the
intracellular phosphatidylserine when the integrity of
the membrane is lost. 99mTc–annexin V binds to
myocytes during the entire spectrum of cellular death,
from early in the apoptotic process to necrosis, and is
therefore a more sensitive and more specific marker of
rejection than is TUNEL.
99mTc–annexin V imaging is similar in concept to
indium 111–labeled antimyosin antibody imaging.26
Antimyosin binds to myosin, which is exposed by
necrotic myocytes.27 Noninvasive indium 111–labeled
antimyosin antibody imaging requires between 24 and
48 hours after injection of radiolabeled antimyosin.
99mTc–annexin V imaging can be performed 1 hour
after injection of the radiopharmaceutical and can
detect both apoptotic and necrotic cell deaths.
When rejection was successfully treated in our exper-
iments, uptake of 99mTc–annexin V returned to baseline.
Histologic examination still showed the presence of
mononuclear cells, but without myocyte damage.
TUNEL imaging confirmed that there were no
myocytes undergoing apoptotic cell death. Clinically,
lymphocytic infiltrates tend to resolve slowly in patients
treated with cyclosporine, and it can take between 2 and
3 weeks after adequate treatment to obtain a clear biop-
sy specimen.22 This clinical observation is consistent
with the histologic pattern seen in this study.
This study indicates that apoptosis occurs during
acute cardiac allograft rejection and disappears after
rejection has been successfully treated. 99mTc–annexin
V imaging can detect apoptosis during cardiac allograft
rejection. Uptake of 99mTc–annexin V correlates well
with histologic grade of acute rejection. Intensity of
uptake of 99mTc–annexin V could provide an indication
of whether a patient needs further analysis and whether
an endomyocardial biopsy is indicated. There is virtu-
ally no circulating blood pool of endogenous annexin
V to compete with binding sites on the phos-
phatidylserine-expressing apoptotic cells or dilute
injected radiolabeled annexin V.16 Because the phos-
Fig 8. Uptake of 99mTc–annexin V in PVG allografts of group III, as a percentage of total body uptake. ACI recipi-
ents received cyclosporine treatment starting on day 4 after transplantation. Uptakes in allografts from group III
were compared on days 1, 4, 11, and 18 after transplantation by a 2-tailed paired Student t test with unequal vari-
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phoserine head group of phosphatidylserine has the
same structure in all species and we used human
annexin V in this study, 99mTc–annexin V promises to
be applicable to human patients.
The results of this study provide the foundation for
refinement of 99mTc–annexin V imaging in a nonhuman
primate study. Clinically, this novel method of nonin-
vasive diagnosis of cardiac allograft rejection could
potentially eliminate the need for routine surveillance
endomyocardial biopsy.
We thank Michael J. Abrams, MD, for kindly providing the
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Discussion
Dr Gregory M. Hirsch (Halifax, Nova Scotia, Canada).
The concept of a method of assessing apoptosis in vivo is
exciting. We have an interest in apoptosis measurements in
chronic rejection, and I have some thoughts about these
issues. Most of your measurements were done early after
transplantation, until day 5, at a time when there is a fair
degree of acute inflammatory infiltrate. Inflammatory cell
death can be confusing at these early times because it can
cause a degree of DNA fragmentation and cause false-posi-
tive staining with TUNEL, which is the gold standard
against which you are measuring the annexin V. When we
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measure apoptosis during a time of acute inflammation, we
take the TUNEL result with a grain of salt and try to rely on
at least some corroborative method, either transmission elec-
tron microscopic morphologic description of apoptotic cell
death, which is fairly characteristic, or DNA laddering. You
lose the in situ representation with DNA laddering, but at
least you can show the actual internucleosomal fragmenta-
tion. Do you have data, or do you have plans to correlate this
annexin V assessment with a more solid assessment, such as
transmission electron microscopic examination or DNA lad-
dering? I think that you are on slightly shaky ground early,
when there is a fair bit of inflammation and there might just
be nonspecific inflammatory cell death driving the apoptot-
ic signal.
Further, do you have data or do you intend to correlate the
annexin V standing with better benchmarks of apoptotic
activity (positive control preparations)? For example, I might
suggest gut lumen, which always has a degree of apoptosis in
the complete absence of inflammation and would be a useful
control preparation.
Dr Vriens. That last is a great suggestion, and your point is
well taken. TUNEL staining indeed indicates DNA cleavage,
which occurs at a later stage of apoptosis, and annexin V
stains apoptotic nuclei at a much earlier stage. We definitely
plan to try to correlate different studies for apoptosis with
annexin V uptake.
